辉瑞:Padcev联合Keytruda能降低特定膀胱癌患者60%的复发、进展或死亡风险,以及50%的死亡风险
辉瑞:Padcev联合Keytruda能降低特定膀胱癌患者60%的复发、进展或死亡风险,以及50%的死亡风险
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.